Feeds:
Posts
Comments

Posts Tagged ‘Risperdal’

*****

TODAY’S NEWS

Forbes: Pfizer‘s history of buying pipeline lemons. This does only tell one side of the story, however – Pfizer has also acquired some pretty major hits.

Speaking of flops, a couple of major experimental drugs aren’t looking so hot these days.

FDA taking another look at some bone drugs, in relation to hip fractures – There have long been safety questions — and lawsuits — over whether bone-building drugs like Merck’s Fosamax can actually increase the chance of femur fractures. Today, the FDA said it was going to take another look at the safety issuesmore

Did J&J plan to break the rules with Risperdal? Business Week reports. Plus, Shire gets a “fourfecta” warning letter from the FDA on one marketing promotion.

RECOMMENDED

Meetings/Events/Launches – Looking for creative and successful providers who can help make your off-site events a hit? We’ve got the partners you need in the Impactiviti network. Contact us (stevew at impactiviti dot com, or phone at 973-947-7429) for recommendations.

PLUS

Nine Simple Steps to Getting Started in Social Media. Good stuff from Dose of Digital blog. For a practical guide on how YOU (as an individual) can put social networking to use building your own Opportunity Network, download my free e-book on that subject.

JUST FOR FUN

———-

Subscribe to the Impactiviti blog via e-mail (which will bring you Impactiviti Daily – a brief of the day’s top pharma news)

Visit the Impactiviti Job Board

Sign up for the Impactiviti Connection twice-monthly e-newsletter (see sample)

***

Read Full Post »

The FDA gives a hint of hope for the long-delayed Eli Lilly/Daiichi Sankyo drug prasugrel. Burrow deep inside this 357-page FDA document just posted online, and you’ll find this jargony but significant sentence: The Division recommends approval of prasugrel for reduction of myocardial infarction in patients with ACS who are managed with PCI.

Glaxo the latest Big Pharma to announce major upcoming cutsBritish drugs company GlaxoSmithKline Plc.  is set to announce about 6,000 job losses when it posts results on Thursday, the Sunday Telegraph newspaper said. The cuts by Glaxo, the world’s second largest drugs company after U.S. group Pfizer, are part of Chief Executive Andrew Witty’s strategy to meet the challenges facing the industry, including increased competition from generic drug makers, the British newspaper said.

Teva gets FDA OK for generic version of J&J‘s Risperdal. And, Takeda gets approval for new GERD drug Kapidex.

——

Subscribe to the Impactiviti blog via e-mail

Subscribe to the Impactiviti blog via RSS

Reblog this post [with Zemanta]

Read Full Post »